September 2022 DAIDS Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.

Note: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Fiscal Year (FY) 2023 Concept

FY 2024 Concepts

Notice of Special Interest (NOSI)–NIH Centers for AIDS Research (CFAR) and NIMH AIDS Research Centers (ARC) Limited Competition for Ending the HIV Epidemic (EHE) Supplement Awards

For the published notice of special interest, check the December 28, 2022 Guide notice, Notice of Special Interest (NOSI): Administrative Supplements to NIH Centers for AIDS Research (CFAR) and NIMH AIDS Research Centers (ARC) for Ending the HIV Epidemic (EHE).

Opportunities for HIV Cure Strategies at the Time of ART Initiation

For the published program announcements with special receipt, referral, and/or review considerations, see the September 19, 2023 Guide announcements, Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed) and Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed).

Pulmonary Outcomes and Sequelae after Treatment - TB (POST-TB)

For the published program announcement with special receipt, referral, and/or review considerations, check the March 30, 2023 Guide announcement, Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional).

Synthetic Nucleic Acid Platforms for HIV-1 (SNAP-H)

For the published notice of funding opportunity, check the April 21 Guide announcement, Synthetic Nucleic Acid Platforms for HIV-1 (SNAPH): (R61/R33, Clinical Trial Not Allowed).

Rational Systematic Characterization and Selection of Adjuvants for HIV Vaccine Candidates (R-CASA)

For the published broad agency announcement, check the February 7, 2023 solicitation, Rational Systematic Characterization and Selection of Adjuvants for HIV Vaccine Candidates (R-CASA).

Innovation for HIV Vaccine Discovery (IHVD)

For the published notice of funding opportunity, check the April 20, 2023 Guide announcement, Innovation for HIV Vaccine Discovery (R01, Clinical Trial Not Allowed).

Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Program

For the published program announcement with special receipt, referral, and/or review considerations, check the October 31, 2022 Guide announcement, Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19, Clinical Trial Not Allowed).

Content last reviewed on